Literature DB >> 32050143

Trajectories of retention in opioid agonist therapy in a Canadian setting.

M Eugenia Socías1, Huiru Dong2, Evan Wood1, Rupinder Brar1, Lindsey Richardson3, Kanna Hayashi4, Thomas Kerr1, M-J Milloy5.   

Abstract

BACKGROUND: Long-term engagement in opioid agonist therapy (OAT) has been consistently associated with reduced risk for morbidity and mortality in people with opioid use disorder (OUD). However, the dynamic nature of engagement/disengagement in OUD care for over time is poorly captured by traditional metrics. We characterized long-term longitudinal trajectories of engagement in OAT in Vancouver, Canada, between 2005 and 2018.
METHODS: Data were derived from two community-recruited prospective cohorts of people who use drugs. Retention in OAT was defined as self-reported enrolment in OAT for two consecutive follow-up periods (an approximately six-month retention interval). We used latent class growth analysis to identify OAT engagement trajectories during the first five years after OAT initiation and multivariable logistic regression to evaluate predictors of trajectory group membership.
RESULTS: We identified four OAT retention trajectories among 438 OAT initiators: "consistently high" (36%), "consistently low" (23%), "increasing" (23%), and "decreasing" (15%). Employment was a significant cross-cutting predictor of membership of all sub-optimal OAT engagement patterns compared to consistently high trajectories. We also found that initiating OAT after 2014 (when regulatory changes to the provincial OAT program were introduced) was associated with the "consistently low" engagement group relative to others.
CONCLUSIONS: We identified four distinct OAT engagement trajectories in Vancouver, Canada, with employment being a common predictor of sub-optimal care trajectories, suggesting the need to explore alternative OAT models to address employment-related barriers. Care trajectory analysis could help inform tailored interventions to specific populations of people with OUD at specific time points to improve engagement in OAT, and decrease opioid-related morbidity and mortality.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Latent class growth analysis; Opioid agonist therapy; Opioid use disorder; Performance measures; Quality metrics

Mesh:

Substances:

Year:  2020        PMID: 32050143      PMCID: PMC7577708          DOI: 10.1016/j.drugpo.2020.102696

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  24 in total

1.  The effects of time and money prices on treatment attendance for methadone maintenance clients.

Authors:  Natalia N Borisova; Allen C Goodman
Journal:  J Subst Abuse Treat       Date:  2004-01

Review 2.  Retention in medication-assisted treatment for opiate dependence: A systematic review.

Authors:  Christine Timko; Nicole R Schultz; Michael A Cucciare; Lisa Vittorio; Christina Garrison-Diehn
Journal:  J Addict Dis       Date:  2015-10-14

3.  Reliability of self-reported human immunodeficiency virus risk behaviors in a residential drug treatment population.

Authors:  J De Irala; C Bigelow; J McCusker; R Hindin; L Zheng
Journal:  Am J Epidemiol       Date:  1996-04-01       Impact factor: 4.897

4.  Ending the Opioid Epidemic - A Call to Action.

Authors:  Vivek H Murthy
Journal:  N Engl J Med       Date:  2016-11-09       Impact factor: 91.245

5.  The validity of drug users' self-reports in a non-treatment setting: prevalence and predictors of incorrect reporting methadone treatment modalities.

Authors:  M W Langendam; H J van Haastrecht; E J van Ameijden
Journal:  Int J Epidemiol       Date:  1999-06       Impact factor: 7.196

6.  Unintended impacts of regulatory changes to British Columbia Methadone Maintenance Program on addiction and HIV-related outcomes: An interrupted time series analysis.

Authors:  M Eugenia Socías; Evan Wood; Ryan McNeil; Thomas Kerr; Huiru Dong; Jean Shoveller; Julio Montaner; M-J Milloy
Journal:  Int J Drug Policy       Date:  2017-04-25

7.  A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.

Authors:  Lucy Burns; Natasa Gisev; Sarah Larney; Timothy Dobbins; Amy Gibson; Jo Kimber; Briony Larance; Richard P Mattick; Tony Butler; Louisa Degenhardt
Journal:  Addiction       Date:  2015-04       Impact factor: 6.526

8.  Barriers to use of free antiretroviral therapy in injection drug users.

Authors:  S A Strathdee; A Palepu; P G Cornelisse; B Yip; M V O'Shaughnessy; J S Montaner; M T Schechter; R S Hogg
Journal:  JAMA       Date:  1998-08-12       Impact factor: 56.272

9.  Factors associated with methadone maintenance therapy discontinuation among people who inject drugs.

Authors:  Ada Lo; Thomas Kerr; Kanna Hayashi; M-J Milloy; Ekaterina Nosova; Yang Liu; Nadia Fairbairn
Journal:  J Subst Abuse Treat       Date:  2018-08-23

10.  Drug and Opioid-Involved Overdose Deaths - United States, 2013-2017.

Authors:  Lawrence Scholl; Puja Seth; Mbabazi Kariisa; Nana Wilson; Grant Baldwin
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-01-04       Impact factor: 17.586

View more
  7 in total

1.  Motivations to initiate injectable hydromorphone and diacetylmorphine treatment: A qualitative study of patient experiences in Vancouver, Canada.

Authors:  Samara Mayer; Al Fowler; Isabella Brohman; Nadia Fairbairn; Jade Boyd; Thomas Kerr; Ryan McNeil
Journal:  Int J Drug Policy       Date:  2020-09-16

2.  Short communication: Relationship between social determinants and opioid use disorder treatment outcomes by gender.

Authors:  Anna Beth Parlier-Ahmad; Maja Radic; Dace S Svikis; Caitlin E Martin
Journal:  Drug Alcohol Depend       Date:  2022-01-28       Impact factor: 4.492

3.  Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting.

Authors:  Elena Argento; M Eugenia Socias; Kanna Hayashi; JinCheol Choi; Lindsay Mackay; Devon Christie; M-J Milloy; Kora DeBeck
Journal:  Int J Drug Policy       Date:  2021-11-07

4.  Trajectories of Retention in Opioid Agonist Therapy and Overdose Risk During a Community-Wide Overdose Epidemic in a Canadian Setting.

Authors:  M Eugenia Socías; Huiru Dong; Evan Wood; Seonaid Nolan; Kanna Hayashi; Thomas Kerr; M-J Milloy
Journal:  Am J Prev Med       Date:  2021-01       Impact factor: 5.043

5.  The use of diverted pharmaceutical opioids is associated with reduced risk of fentanyl exposure among people using unregulated drugs in Vancouver, Canada.

Authors:  M Eugenia Socias; Cameron Grant; Kanna Hayashi; Geoff Bardwell; Mary Clare Kennedy; M-J Milloy; Thomas Kerr
Journal:  Drug Alcohol Depend       Date:  2021-09-25       Impact factor: 4.492

6.  Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder.

Authors:  Davida M Schiff; Timothy C Nielsen; Bettina B Hoeppner; Mishka Terplan; Scott E Hadland; Dana Bernson; Shelly F Greenfield; Judith Bernstein; Monica Bharel; Julia Reddy; Elsie M Taveras; John F Kelly; Timothy E Wilens
Journal:  Am J Obstet Gynecol       Date:  2021-04-15       Impact factor: 10.693

7.  High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder.

Authors:  Andrew A Herring; Aidan A Vosooghi; Joshua Luftig; Erik S Anderson; Xiwen Zhao; James Dziura; Kathryn F Hawk; Ryan P McCormack; Andrew Saxon; Gail D'Onofrio
Journal:  JAMA Netw Open       Date:  2021-07-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.